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Abstract
Type 1 diabetes is caused by the destruction of insulin producing beta cells by the immune
system. The p110δ isoform of PI3K is expressed primarily in cells of haematopoietic origin
and the catalytic activity of p110δ is important for the activation of these cells. Targeting of
this pathway offers an opportunity to reduce immune cell activity without unwanted side
effects. We have explored the effects of a specific p110δ isoform inhibitor, IC87114, on dia-
betogenic T cells both in vitro and in vivo, and find that although pharmacological inhibition
of p110δ has a considerable impact on the production of pro-inflammatory cytokines, it
does not delay the onset of diabetes after adoptive transfer of diabetogenic cells. Further,
we demonstrate that combination treatment with CTLA4-Ig does not improve the efficacy of
treatment, but instead attenuates the protective effects seen with CTLA4-Ig treatment
alone. Our results suggest that decreased IL-10 production by Foxp3+ CD4+ T cells in the
presence of IC87114 negates individual anti-inflammatory effects of IC8114 and CTLA4-Ig.
Introduction
Type 1 diabetes is an autoimmune inflammatory disease that is caused by immune cell medi-
ated destruction of the insulin-producing beta cells in the pancreas. T cells are assumed to play
a considerable role in the pathogenesis of this disease which comes from the demonstration
that its strongest genetic risk is conferred by the HLA locus and other loci affecting the biology
of these cells [1, 2]. Islet specific CD4+ and CD8+ cells mediate diabetogenesis in NODmice [3]
and have been identified in human type 1 diabetes patients [4–6]. Other cell types including B
cells, dendritic cells and macrophages are also necessary for the initiation of the anti-islet
immune responses (reviewed in [7]). Once the beta cell pool is destroyed by the immune sys-
tem, insufficient amounts of insulin are produced to sustain glucose uptake into insulin
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dependent cells, notably muscle cells, causing wasting due to protein breakdown, even though
high levels of glucose are present in the blood. The disease was fatal until Banting and Best dis-
covered insulin in 1922 [8]. Although much has been learned about type 1 diabetes since then,
no protocols for sustained cure or prevention have been discovered. Strategies attempting to
abrogate immune responses have been successful in mouse models [7], and some have also
resulted in delay of beta cell destruction in patients, such as the anti-CD3 treatment clinical tri-
als [9, 10] and CTLA-4 Ig [11].
CTLA-4 Ig prevents the activation of T cells by inhibiting interaction with the co-stimula-
tory molecule CD28. However, CD28 blockade alone is unlikely to be sufficient to prevent
autoimmunity due to the fact that memory and CD8+ T cells are not as dependent as naïve
CD4+ T cells on CD28 costimulation. As none of the clinical trials have resulted in long term
reversal of diabetes, it has been suggested that a combination of treatments targeting various
stages of immune activation may be more successful [12]
A widely explored approach is the inhibition of key signalling enzymes involved in the activa-
tion and metabolism of immune cells. PI3Ks constitute a family of enzymes involved in cellular
functions such as cell growth, proliferation, differentiation, motility, survival and intracellular
trafficking [13]. The class I PI3Ks catalyse the final step to PIP3 by phosphorylating PI(4,5)P2 to
become PI(3,4,5)P3. PIP3 activates Akt, which in turn leads to activation of mTOR and inhibi-
tion of Foxo. Of the four class I PI3K subunits, PI3K p110δ is uniquely expressed in immune
cells [14]. Specific inhibition of this subunit therefore primarily affects cells of the immune sys-
tem, leaving other cell types unchanged. p110δ inhibitors such as IC87114 have been used to
inhibit p110δ activity in vitro and in vivo. It has been shown that IC87114 inhibits TCR-induced
cytokine production by both naïve and effector T cells [15]. In addition to its effects on T cells,
p110δ inhibitors also target other immune cells such as B cells, NK and myeloid cells (reviewed
in [14, 16] The typical outcome of PI3Kδ inactivation is a reduction but not a complete abro-
gation of leukocyte functions, probably due to the overlapping functions with other PI3K mem-
bers that are also present in leukocytes. IC87114 reduced disease severity in preclinical rodent
models of rheumatoid arthritis, asthma, and allergy [17–19]. The PI3Kδ inhibitor idelalisib was
approved in 2014 for the treatment of chronic lymphocytic leukaemia.
CD28 and p110δ act synergistically to provide full T-cell stimulation [20], and we hypothe-
sised that dual inhibition of CD28 and p110δmay achieve more potent alleviation of patho-
logic immune responses than can be achieved with either inhibitor alone. To test this
hypothesis, we used IC and CTLA-4 Ig, either alone or in combination, to inhibit signalling via
p110δ, CD28 or both in naïve and activated T cells from non obese diabetic (NOD) mice and
TCR transgenic mice on a NOD background, and monitored proliferation and cytokine pro-
duction. In addition, we have investigated whether such a combination could limit the develop-
ment of autoimmune diabetes in the NODmouse model after the transfer of either naïve or
activated islet reactive BDC2.5 CD4+ T cells.
Materials and Methods
Mice
Female NOD, NOD-scid, BDC2.5 NODmice [21] NOD-CD2-GFP mice [22], G9C8 TCR
transgenic NODmice [23, 24] and NOD-Foxp3-GFP [25] were bred in the Department of
Pathology, University of Cambridge and maintained under specific pathogen—free conditions.
The mice are housed in individually ventilated cages with free access to standard chow and
water. The facility is kept on a 12 hour light, 12 hour dark cycle. The humane endpoints for
these experiments specify that any mouse that loses more than 15% of its body weight (com-
pared to healthy littermates), or in other ways looks unwell and likely to exceed the Home
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Office standard of moderate severity must be culled. However, no mice used in this study
required early culling. At the end the experiments, mice were culled using a CO2-chamber fol-
lowed by dislocation of the neck. In cases where we were harvesting islets for transplantation it
was important to maintain an intact bile duct, and death was instead confirmed through palpa-
tion of the chest to assess the absence of a heart beat.
Ethics statement
This study was carried out in strict accordance with U.K. Home Office project licence regula-
tions (Project Licence number 80/2442) after approval by the Ethical Review Committee of the
University of Cambridge.
PI3K-δ inhibitor
The PI3K p110δ inhibitor IC87114 was synthesized by Jonathan Clark (Babraham Institute) as
described (D030 from patent WO 01/81346) [15]. For in vivo administration, IC87114 was dis-
solved in methyl cellulose 400 cps (Sigma) using a sonicator (Heat Systems Ultrasonics), and
administered through oral gavage twice daily in 100μl at a dose of 30mg/kg body weight. This
dose was chosen based on previous reports of its efficacy in vivo [17]. In our hands, a 30 mg/kg
by gavage achieves ~2 μM 90 min post-administration and the drug is cleared from the blood
4–7 hours post administration. IC87114 is selective for p110δ at plasma concentrations of
5 μM [17].
CTLA4-Ig
CTLA4-Ig (Abatacept) was provided by Bristol Myers Squibb (BMS). CTLA4-Ig was adminis-
tered by intraperitoneal (ip) injection starting on day 0 with 500 μg, then 250μg every other
day [26]. For in vitro assays, CLTA4-Ig was added to cultures at 100 ng/ml.
Th1 differentiation for in vitro studies and adoptive transfer
CD4+CD25- T cells (for in vitro studies) or CD4+CD62Lhi CD25-B220- T cells (for adoptive
transfer) were isolated by cell sorter from 5-week-old BDC2.5 TCR transgenic NODmice and
differentiated into Th1 cells by culturing them with plate bound anti-CD3 (2μg/mL), soluble
anti-CD28 (10μg/mL), IL-2 (100u/ml), IL-12 (10ng/ml) and IFN-γ (100u/ml) for 4 days at
37°C with 5% CO2. Afterwards, the production of IFN-γ was checked by specific ELISA
(R&D).
T cell activation for functional assays
Cells were isolated from spleen and lymph nodes and cultured in IMDM with 10% fetal calf
serum, 1% penicillin-streptomycin, and β-mercaptoethanol. 2x105 total lymphocytes were
stimulated as appropriate (see below) for 3 days in the presence or absence of rising concentra-
tions of IC (0.6, 1.25, 2.5, 5 and 10μg/mL) at 37°C with 5% CO2. NODmouse cells were stimu-
lated with plate bound anti-CD3 (2μg/mL) and soluble anti-CD28 (10μg/mL), whereas cells
isolated from BDC2.5 or G9C8TCR transgenic NODmice were stimulated with BDC2.5
mimotope or insulin peptide insB 15–23, respectively. In other experiments, 2.5x105 Th1 cells
were cultured with 1x104 APCs and BDC2.5 mimotope (0.5μg/mL) with or without increasing
concentrations of IC as previously described for 72 hours. Cells cultured in the presence of the
proliferative stimulus but without IC87114 were positive controls, whereas non-stimulated
cells were negative controls.
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Proliferation and cytokine analysis
In all experiments proliferation was assessed by CFSE staining (5μM). After gating on CD4+
and/or CD8+ T cells, the percentage of proliferating cells in each population was determined.
For cytokine analysis, supernatants were taken at the end of the time cultures and IFN-γ pro-
duction or IL-10 was assessed by specific ELISA (R&D Systems). Levels of other cytokines were
detected using a cytometric bead array (eBioscience). For intracellular cytokine staining, cells
were washed and stimulated with PMA (50 ng/mL) and ionomycin (2000 ng/mL) for 5 hours.
BFA (5μg/mL) was added for the last 3 hours. Afterwards, the staining of cell surface markers
was performed. Cells were washed, fixed, permeabilized (intracellular cytokine staining kit,
eBioscience), and stained for detection of IFN-γ.
In vitro assessment of regulatory T cells
CD4+ CD25+ GFP+ cells from spleens and lymph nodes of 5-week-old Foxp3/GFP+ BDC2.5
TCR transgenic NODmice were isolated by cell sorter (MoFlo, BD). Tregs were cultured with
anti-CD3 (5 μg/mL), anti-CD28 (20μg/mL) and IL-2 (1000 u/ml) with or without IC87114 (5
and 10μM) for 72 hours. Proliferation was assessed by dilution of CFSE staining (5μM, Invitro-
gen) after gating on CD4+CD25+ cells. Supernatants were assessed for IL-10 by specific ELISA
(R&D). Positive control cells were stimulated with anti-CD3/28 antibodies and IL-2 whereas
negative control cells were not stimulated at all.
Islet transplantation
Diabetes was induced in recipient mice (normal (WT), CD28-/-, p110δD910A/D910A and
CD28-/-; p110δD910A/D910A double knockouts (DKOs)) by streptozotocin injection. All strains
were backcrossed on the C57BL/6 background. Islets were prepared fromMHC-mismatched
donors (Cba1-C57BL/6 F1). Pancreatic islets were isolated through inflation of the pancreas
via the bile duct [27], and islet transplantation was performed according to standard protocols
[28]. Confirmed diabetic recipient mice received between 300 and 500 islets, giving approxi-
mately 15 islets per gram of body weight. We anaesthetised the recipient mice with isoflurane
inhalation anaesthesia, and gave them sc temgesic for post-surgery analgesia. Islets were
injected beneath the kidney capsule of female recipients that have been confirmed to be dia-
betic after the streptozotocin injection (Blood glucose level> 20 mM at two consecutive read-
ings). Blood glucose was assessed three times per week for the period of graft survival, and
daily at the onset of graft rejection—for a maximum of three days. Some mice which retained
their grafts for longer than 100 days had the engrafted kidney removed at the end of the experi-
ment to ascertain that the graft was responsible for the restoration of euglycemia.
Adoptive transfer models
CD4+ T cells were isolated by cell sorting from spleen and lymph nodes of BDC2.5 TCR trans-
genic mice. 1x106 CD4+ T cells were transferred by the ip route to 5-week old NOD-scid mice.
Mice received IC87114 treatment (30mg/Kg) by oral gavage twice per day and/or CTLA-4 Ig
administrated by the ip route at a concentration of 500μg/mL (the first time) and then 250μg/
mL every other day from day 0 to 10. Positive control mice did not receive any treatment. After
day 7, mice were monitored for the development of diabetes by measuring blood glucose or
urine glucose levels with Diastix strips (Bayer) every day. In other experiments, 5x105 Th1 cells
(see above) were transferred by the ip route to 5-week old NODmice. Mice received the same
treatment as described above, but from day 0 to 5. After day 3, mice were monitored for the
development of diabetes as previously described.
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Statistical analysis
Differences between groups were tested using the student t-test, significant p-values are indi-
cated with  (p0.05),  (p0.001) or  (p0.0001). Differences between animals regarding
diabetes incidence or recurrence after islet transplant were tested using the Log rank survival
test, with actual p-values displayed within the relevant figure or legend. All analysis was per-
formed using GraphPad Prism software.
Results
IC87114 inhibition of the PI3K p110δ subunit does not diminish T cell
proliferation but has profound effects on cytokine production
We assessed the effects of increasing levels of IC87114 on T cells from diabetes-prone NOD
mice in in vitro culture, looking at anti-CD3 and anti-CD28 induced proliferation of CD4+ T
cells (Fig 1A, left hand panel) and CD8+ T cells (Fig 1A, right hand panel) and production of
IFN-γ (Fig 1B). We found that the presence of IC87114 did not suppress proliferation of either
CD4+ or CD8+ T cells (Fig 1A) but that the production of IFN-γ was severely impaired even at
the lowest concentration of IC87114 tested (Fig 1A). Unaffected proliferation (as measured by
% of cells divided1 time) and suppressed IFN-γ production were seen both in islet specific
TCR transgenic BDC2.5 CD4+ T cells [21] (Fig 1C and 1D), which recognise a posttranslation-
ally modified peptide of chromogranin A [29], and in TCR transgenic G9C8 CD8+ T cells
which recognise an insulin peptide [23, 24] (Fig 1E and 1F). We performed an extended analy-
sis of the effects on cytokine production by IC87114, and found that increasing concentration
of IC87114 suppressed all the pro-inflammatory cytokines assessed in supernatants from pep-
tide-stimulated BDC2.5 CD4+ T cells, including IFN-γ, IL-2, GM-CSF, and IL-6, while there
was a trend towards increased production of anti-inflammatory cytokine IL-10 and Th2 associ-
ated cytokines IL-4 and IL-5 (S1 Fig). Production of the cytokines that could be detected in
supernatants from insulin peptide stimulated G9C8 CD8+ T cells was also decreased, with
lower levels of IFN-γ, IL-2, TNF, IL-17, GM-CSF, IL-10 and IL-6 recorded even at the lowest
concentrations of added IC87114 (S2 Fig). An interesting finding was that T cell proliferation
was if anything increased in the presence of higher concentrations of IC87114, with more cells
dividing several times (S3A Fig) and with BDC2.5 CD4+ T cells upregulating CD25 in response
to increasing concentration of IC87114 (S3B Fig).
Administration of IC87114 via oral gavage does not delay onset of
diabetes after BDC2.5 cell transfer into NOD-scid recipients
As production of proinflammatory cytokines is central to the process whereby islet-specific T
cells cause type 1 diabetes through incapacitating and killing beta cells [30], we wanted to test
whether oral administration of IC87114 could prevent or delay onset of diabetes in NODscid
mice after transfer of potentially diabetogenic islet-specific BDC2.5 CD4+ T cells. We found
that oral administration of 30mg/kg body weight twice per day (Fig 2A) had no effect of the
development of diabetes after cell transfer, as all mice in both groups had developed diabetes
by day 13 after transfer (Fig 2B).
IC87114 suppresses IFN-γ production from Th1-differentiated islet
specific effector T cells but does not stop them from causing diabetes
after transfer into wt NOD recipients
As IC87114 did not have an effect on development of diabetes after transfer of BDC2.5 cells we
wished to elucidate whether it could decrease IFN-γ production from already Th1
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Fig 1. IC87114 blocks IFN-γ production by activated NOD cells.Cells isolated from the spleens and lymph nodes of regular NODmice (A,B); BDC2.5
TCR transgenic NODmice (C,D) or G9C8 TCR transgenic NODmice (E,F) were stimulated with anti-CD3/28 antibodies (A, B), BDC2.5 mimotope (C, D) or
insulin peptide (E, F), respectively, with or without increasing concentrations of IC87114 (0.6–10μM) for 72 hours. (A,C,E) Cells were stained with CFSE and
after gating on CD4+ and/or CD8+ T cells, the percent of proliferating cells in each population was determined. (B) Supernatants were collected and IFN-γ
production was assessed by specific ELISA (B) or intracellular staining (D, F). All data were expressed as the mean ± SD for triplicate samples, differences
between groups were tested using the student t-test. The data is representative of at least three independent experiments.
doi:10.1371/journal.pone.0146516.g001
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differentiated effector CD4+ T cells. We found that, just as seen in in vitro cultures with naïve
cells, the Th1 differentiated effector cells proliferated equally well in the presence of IC87114
(Fig 3A), but that their IFN-γ production, although more robust than from naïve T cells, was
decreased by IC87114 in a dose-dependent way (Fig 3B). Th1 differentiated effector BDC2.5
CD4+ T cells cause diabetes after transfer into wildtype NODmice in a process heavily depen-
dent on production of IFN-γ (Fig 4A) [30], and we hypothesised that administration of
IC87114 via oral gavage which can stop IFN-γ production from these cells in vitro, would
inhibit or delay onset of diabetes in the IFN-γ dependent model of disease. However, oral
administration of 30mg/kg body weight twice per day from the day of cell transfer did not
affect disease development, and both the IC87114-treated and the vehicle treated group devel-
oped diabetes on day 5 after adoptive transfer (Fig 4B). Oral administration did not appear to
affect IFN-γ production in vivo as cells isolated from pancreas (Fig 4C) or pancreatic lymph
nodes (Fig 4D) of IC87114 or vehicle-treated mice produced equal amounts of IFN-γ.
Combination with CTLA4-Ig does not alter or potentiate the in vitro
effects of IC87114
As IC87114 showed no effect on in vivo diabetes development despite its dramatic effects on
cytokine production in vitro, we hypothesised that a combination with another agent that tar-
gets a different pathway leading to the activation of T cells might synergise with the IC87114.
Indeed, in work leading up to the current study, we found that p110δ-CD28 double knockout
mice are immune suppressed and failed to reject allogeneic islet grafts ([20] and S4 Fig). Since
Fig 2. Administration of IC87114 does not prevent diabetes after adoptive transfer of naïve diabetogenic cells.CD4+ T cells were isolated by cell
sorting from spleen and lymph nodes of BDC2.5 TCR transgenic mice. 1x106 CD4+ T cells were transferred i.p. route to NOD-scidmice. Mice received
IC87114 treatment (30mg/Kg) by oral gavage (2x/day) from day 0 to 10 (A). Positive controls are mice that received CD4+ T cells from BDC2.5 mice without
any other treatment. After this time, blood glucose levels were checked every day, and mice were considered irrevocably diabetic and sacrificed when they
reached two consecutive blood glucose levels >13mM (B).
doi:10.1371/journal.pone.0146516.g002
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CTLA-4 Ig inhibits the ability of T cells to receive signals via CD28, we assessed the effects of
combining increasing levels of IC87114 with CTLA4-Ig on T cells from NODmice in in vitro
culture, looking at anti-CD3 induced proliferation of CD4+ T cells (Fig 1A, left hand panel)
and CD8+ T cells (Fig 1A, right hand panel) and production of IFN-γ (Fig 1B). We found that
the combination of CTLA4-Ig with IC87114 did not suppress proliferation of either CD4+ or
CD8+ T cells any differently than IC87114 on its own (Fig 5A) and that the production of IFN-
γ was similarly impaired in the presence of CTLA4-Ig (Fig 5B) compared with IC87114 alone
(Fig 1B). The presence of CTLA4-Ig modestly impaired proliferation of BDC2.5 CD4+ T cells,
but this was not potentiated by increasing concentrations of IC87114 (Fig 5C). However,
CTLA4-Ig did have a significant effect on the production of IFN-γ from the BDC2.5 CD4+ T
cells, and combination with IC87114 decreased IFN-γ production even further (Fig 5D). The
proliferation and IFN-γ production of G9C8 CD8+ T cells was not affected by the addition of
CTLA4-Ig (Fig 5D and 5E), demonstrating the same reduction of IFN-γ production in
response to IC87114 as when no CTLA4-Ig was present (Fig 1F). We performed an extended
analysis of the effects on cytokine production by combining CTLA4-Ig and IC87114, and
found that addition of CTLA4-Ig on its own decreased the production of IL-2 in supernatants
from peptide-stimulated BDC2.5 CD4+ T cells, but that other cytokines assessed demonstrated
no additional downregulation in response to the additional presence of CLTA4-Ig to the
increasing concentrations of IC87114 in the culture (S5 Fig). We did not detect an effect of
CTLA-4 Ig with the bead array, which could be due to the fact that the high concentration of
IFN-γ in the samples exceeding the top limit of the assay (S5 Fig).
Combination treatment with CTLA4-Ig does not increase protection from
diabetes by IC87114
As production of IFN-γ was further decreased in BDC2.5 CD4+ T cells in vitro when CTLA4-Ig
was added to IC87114 in culture, we tested whether oral administration of IC87114 in combi-
nation with CTLA4-Ig could prevent or delay onset of diabetes in NOD scid mice after transfer
Fig 3. IC87114 reduces IFN-γ production by differentiated Th1 cells.Cells isolated from the spleens and lymph nodes of BDC2.5 TCR transgenic NOD
mice were differentiated into Th1 cells by culturing them in the presence of anti-CD3/CD28 antibodies, IL-2, IL-12 and IFN-γ for 4 days. 2.5x105 Th1 cells
were then cultured with 1x104 APCs and BDC2.5 mimotope (0.5 μg/mL) with or without increasing concentrations of IC87114 (0.6–10μM) for 72 hours. Cells
were stained with CFSE and after gating on CD4+ T cells, the percent of proliferating cells was determined (A). Supernatants were collected and IFN-γ
production was assessed by specific ELISA (B). All data were expressed as the mean ± SD for triplicate samples. The results are representative of at least
three independent experiments, differences between groups were tested using the student t-test.
doi:10.1371/journal.pone.0146516.g003
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of BDC2.5 CD4+ T cells (Fig 6A). We found that intraperitoneal injections of CTLA4-Ig every
other day for the first 10 days after transfer significantly delayed onset of diabetes in recipient
mice (Fig 6B), but that combination with twice daily administration of IC87114 did not
enhance the protective effect, but rather appeared to attenuate it (Fig 6B).
Combination with CTLA4-Ig does not alter or potentiate the in vitro or in
vivo effects of IC87114 on Th1 differentiated effector T cells
We also assessed whether addition of CTLA4-Ig had an additional inhibitory affect on IFN-γ
production from already Th1 differentiated effector CD4+ T cells. We found that, just as seen
in Fig 3, that the Th1 differentiated effector cells proliferated equally well in the presence of
IC87114 (Fig 3A), but that their IFN-γ production, although more robust than from naïve T
cells, was decreased by IC87114 in a dose dependent way. Addition of CTLA4-Ig to the culture
had no effect on proliferation (Fig 7A), and had some effect on IFN-γ production, not appear-
ing to result in synergistic suppression (Fig 7B). Neither treatment with CTLA4-Ig on its own
nor in combination with IC87114 affected development of diabetes after transfer of Th1 differ-
entiated effector BDC2.5 CD4+ T cells into wt NODmice (Fig 7C), as all mice regardless of
treatment developed diabetes 5 to 6 days after injection of the diabetogenic cells.
Fig 4. IC87114 treatment does not reduce the incidence of diabetes after adoptive transfer of Th1 cells to wt NODmice. CD4+, CD62Lhi, CD25lo B220
lo T cells were isolated by cell sorting from spleen and lymph nodes of BDC2.5 TCR transgenic mice and differentiated into Th1 cells by culturing them in the
presence of anti-CD3/CD28 antibodies, IL-2, IL-12 and IFN-γ for 4 days. 5x105 Th1 cells were transferred i.p. to wt NODmice and IC87114 (30mg/Kg) or
vehicle were administrated by oral gavage twice daily from day 0 to 5 (A). Mice were considered diabetic after 2 consecutive blood glucose readings > 13mM
(B). We assessed the percentages of IFN-γ-producing CD4+T cells from pancreatic lymph nodes (C) and pancreas (D) in vehicle treated mice, IC87114
treated mice and negative control mice (4 mice per group). Negative control NODmice did not receive Th1 cells nor any treatment.
doi:10.1371/journal.pone.0146516.g004
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IC87114 does not alter the percentage of regulatory T cells, but reduces
their production of IL-10
Treatment with IC87114 appeared to break the temporary tolerance afforded by CTLA4-Ig
treatment after islet specific T cell transfer (Fig 6B). As the effects of IC87114 on the cytokine
production of these cells were so striking, we wondered if effects of IC87114 on the regulatory
T cell pool could be even more important, and thus cancel out and even override any anti-
inflammatory effects. We found that oral administration of IC87114 had no effect on the per-
centages of Treg present in the spleen, inguinal or pancreatic lymph nodes of treated mice (Fig
Fig 5. Combination of CTLA4-Ig with IC87114 has nomajor effect on diabetogenic cells. Cells isolated from the spleens and lymph nodes of wild-type
NODmice (A,B); BDC2.5 TCR transgenic NODmice (C,D) or G9C8 TCR transgenic NODmice (E,F) were stimulated with anti-CD3/28 antibodies (A, B),
BDC2.5 mimotope (C, D) or insulin peptide (E, F), respectively, with or without increasing concentrations of IC87114 (0.6–10μM), with or without CLTA4-Ig
(100 ng/ml) as indicated, for 72 hours. Cells were stained with CFSE and after gating on CD4+ and/or CD8+ T cells, the percent of proliferating cells in each
population was determined (A,C,E). IFN-γ production was assessed either through ELISA (B) or intracellular staining (D, F). All data were expressed as the
mean ± SD for triplicate samples, differences between groups were tested using the student t-test. The data is representative of at least three independent
experiments.
doi:10.1371/journal.pone.0146516.g005
PI3Kδ Inhibition Does Not Inhibit T Cell Mediated Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0146516 January 19, 2016 10 / 17
8A) or on their absolute numbers (data not shown), and that presence of IC87114 in culture
medium did not affect proliferation of sorted Treg from Foxp3-GFP reporter NODmice in
vitro (Fig 8B). However, we found that cytokine production was strongly affected by IC87114,
demonstrating a ~65% drop in IL-10 production in the presence of 5mM IC87114 (Fig 8C).
Discussion
IC87114 has a profound suppressive effect on the production of proinflammatory cytokines
such as IFN-γ and IL-17 as well as IL-2 from islet-specific cells activated in vitro, while increas-
ing the production of anti-inflammatory cytokines such as IL-4 and IL-10. As the development
of diabetes in NODmice depends on the production of IFN-γ from CD4+ T cells [30], and
IFN-γ production and IL-17 production is elevated in islet-reactive CD4+ T cells in recent
onset type 1 diabetes patients [5, 31], we hypothesised that administration of IC87114 could
have beneficial effects on anti-islet inflammation and be a feasible option of type 1 diabetes
therapy. A previous study has demonstrated modest positive effects of IC87114 on the
Fig 6. Combination treatment with CTLA4-Ig and IC87114 does not prevent diabetes after adoptive transfer of naïve diabetogenic cells.CD4+ T
cells were isolated by cell sorting from spleen and lymph nodes of BDC2.5 TCR transgenic mice. 1x106 CD4+ T cells were transferred i.p. route to NOD-scid
mice. Mice received IC87114 treatment (30mg/Kg) or vehicle by oral gavage (2x/day) from day 0 to 10, and/or ip injections of CTLA4-Ig on day 0, 3 and 5 (A).
Positive control mice received CD4+ T cells from BDC2.5 mice without any other treatment. Blood glucose levels were checked every day from day 7, and
mice were considered irrevocably diabetic and sacrificed when they reached two consecutive blood glucose levels >13mM (B). Differences between
treatment groups were determined using the Log Rank survival test.
doi:10.1371/journal.pone.0146516.g006
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development of diabetes in NODmice [32], and we hypothesised that combination of this
agent which has such dramatic effects on production of pro-inflammatory cytokines even from
already activated cells [15] with another well tolerated treatment targeting the activation of T
cells [11, 26] would have a chance of preventing disease completely. Indeed, preliminary stud-
ies showed that genetic inactivation of PI3Kδ and CD28 resulted in indefinite acceptance of
islet allografts.
However, we found that, despite seeing considerable inhibition of pro-inflammatory cyto-
kine production even at the lowest concentrations of IC87114 tested, treatment with IC87114
Fig 7. Combined treatment of IC87114 and CTLA-4 Ig does not reduce the incidence of diabetes in the adoptive transfer model of Th1 cells from
BDC2.5 transgenic mice to NODmice.CD4+, CD62Lhi, CD25lo B220 lo T cells were isolated by cell sorting from spleen and lymph nodes of BDC2.5 TCR
transgenic mice and differentiated into Th1 cells by culturing them in the presence of anti-CD3/CD28 antibodies, IL-2, IL-12 and IFN-γ for 4 days. Th1 cells
were then cultured with 1x104 APCs and BDC2.5 mimotope (0.5 μg/mL) with or without increasing concentrations of IC87114 (0.6–10μM)), with or without
CTLA4-Ig (100 ng/ml) as indicated, for 72 hours. Cells were stained with CFSE and after gating on CD4+ T cells, the percentage of proliferating cells was
determined (A). Supernatant IFN-γ assessed by specific ELISA (B). All data expressed as the mean ± SD for triplicate samples, differences between groups
were tested using the student t-test. The results are representative of at least three independent experiments. 5x105 Th1 cells were transferred i.p. to wt NOD
mice. IC87114 (30mg/Kg) or vehicle were administrated by oral gavage twice daily from day 0 to 5, and/ CTLA4-Ig injected ip on day 0, 3 and 5. The number
of mice per group is indicated within the Fig Mice were considered diabetic after 2 consecutive blood glucose readings > 13mM (C).
doi:10.1371/journal.pone.0146516.g007
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had no effect on the development of diabetes either after adoptive transfer of naïve BDC2.5
CD4+ T cells into NOD scid mice or after transfer of Th1 differentiated effector BDC2.5 CD4+
T cells into wild type NODmice. The group sizes we used for in vivo experiments were small,
and it cannot be excluded that differences between groups could have been detected had the
sample size been larger. However, as no positive effects of IC87114 were detected in the prelim-
inary in vivo experiments, we decided against using larger numbers of mice which might have
allowed us to detect subtle differences between groups.
Adding CTLA4-Ig to cultures had specific effects, targeting CD4+ T cell proliferation and
production of IL-2 from these cells, and combination of CLTA4-Ig with IC87114 had a major
effect on IFN-γ production from CD4+ T cells. This was considered promising as IFN-γ pro-
duction from CD4+ T cells that has been shown to be particularly important in the pathology
Fig 8. IC87114 does not affect percentages of Foxp3+ Treg in treatedmice, but reduces IL-10 production from Treg. Percentages of Foxp3+ cells
were assessed in spleen, inguinal lymph nodes and pancreatic lymph nodes of mice treated with IC87114 twice daily for 10 days. Each data point represents
one mouse (A). Proliferation of sorted CFSE labeled BDC2.5 Foxp3-GFP cells in response to anti-CD3/CD28 antibodies in the presence of IC87114 (B).
Production of IL-10 from stimulated, sorted, BDC2.5 Foxp3-GFP in presence of IC87114 measured by supernatant ELISA (C). Results are representative of
at least two experiments.
doi:10.1371/journal.pone.0146516.g008
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of diabetes in mice as well as men [5, 30]. However, combination treatment with twice daily
oral administration of IC87114 and intraperitoneal injections with CTLA4-Ig every other day
for 10 days did not lead to protection from diabetes either after transfer of naïve cells or pre-
activated Th1 cells. In fact, treatment with IC87114 appeared to attenuate the protective effect
afforded by CTLA4-Ig injection, raising the question of whether effects on the regulatory T cell
subset may be greater than any effects on anti-inflammatory cytokine production. We found
that although IC87114 treatment did not change the percentage of Foxp3+ regulatory CD4+ T
cells present in secondary lymphoid organs, these cells produced less anti-inflammatory IL-10
when activated in the presence of IC87114, and are thus also a feasible targets of IC87114 treat-
ment. Production of anti-inflammatory cytokines such as IL-10 [33] and TGF-β is known to
suppress development of diabetes in NODmice [34, 35], and it is not surprising that a reduc-
tion in the production of anti-inflammatory cytokines could precipitate disease.
Regulatory T cells have been identified as a target of PI3K p110δ inhibitors, and targeting
p110δ signalling in these cells increases anti-tumour immune responses by releasing cytotoxic
CD8+ T cells from Treg control [36, 37] even though lack of p110δ signalling also resulted in
decreased CD8+ T cell expression of activation marker CD44 as well as granzyme B and per-
forin. Our findings demonstrate major effects of IC87114 on the production of pro-inflamma-
tory cytokines from diabetogenic T cell clones in vitro, but no decrease in their diabetogenicity
in vivo. In fact, we see that treatment with IC87114 abrogates the protective effects of
CTLA4-Ig treatment and causes a quicker progression to diabetes after cell transfer. Our results
indicate that IC87114 is not a promising candidate for treatment of type 1 diabetes, even in
combination with other drugs such as CTLA4-Ig, but that it leaves the in vivo inflammatory
response unchanged. Instead, our data adds weight to the proposal that PI3K p110δ inhibition,
as a means to reduce the effect of Treg, is a feasible strategy for breaking tumour-specific
immune tolerance to achieve improved cancer immunotherapy.
Supporting Information
S1 Fig. Effects of IC87114 on cytokine production in BDC2.5 CD4+ T cells. Cells isolated
from the spleens and lymph nodes of BDC2.5 TCR transgenic NODmice were stimulated with
the BDC2.5 mimotope (0.5 μg/mL) with or without increasing concentrations of IC87114
(0.6–10μM) for 48 hours. Cytokines from supernatants were assessed in duplicate using a bead
cytokine array, differences between groups were tested using the student t-test.
(TIF)
S2 Fig. Effects of IC87114 on cytokine production in G9C8 CD8+ T cells. Cells isolated from
the spleens and lymph nodes of G9C8 TCR transgenic NODmice were stimulated with the
insulinB 15–23 peptide (0.5 μg/mL) with or without increasing concentrations of IC87114
(0.6–10μM) for 48 hours. Cytokines from supernatants were assessed in duplicate using a bead
cytokine array, differences between groups were tested using the student t-test.
(TIF)
S3 Fig. Effects of IC87114 on the distribution of divisions and activation status. Cells iso-
lated from the spleens and lymph nodes of BDC2.5 TCR transgenic NODmice were stimulated
with the BDC2.5 mimotope (0.5 μg/mL) with or without increasing concentrations of IC87114
(0.6–10μM) for 72 hours, and then stained for CD25 A histogram overlay of representative cul-
tures gated on CD4+ cells (A, left) and a graph showing all data (A, right). Cells isolated from
the spleens and lymph nodes of G9C8 TCR transgenic NODmice were stained with CFSE and
stimulated with the insulinB 15–23 peptide (0.5 μg/mL) with or without increasing concentra-
tions of IC87114 (0.6–10μM) for 72 hours. A histogram overlay of representative cultures
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gated on CD8+ cells (B, left), and a graph showing all data (B, right). Differences between
groups were tested using the student t-test.
(TIF)
S4 Fig. Survival of MHCmis-matched islets in streptozotocin induced diabetic recipients.
Wt C57BL/6 mice, CD28 KO, PI3K p110D910A (D910A) and CD28-D910A double deficient
mice (DKO) were rendered diabetic through injection of streptozotocin. Diabetic mice received
a MHCmis-matched (Cba1-C57BL/6 F1 donor) islet graft under the kidney capsule. Blood
glucose was monitored in the recipient mice for up to 215 days. Some DKOmice that remained
euglycemic for a long time underwent nephrectomy at the end of the experiment to ascertain
that the graft was the cause of the restored euglycemia. The difference in euglycemic survival
between wt recipient mice and DKO recipient mice was assessed using the Log Rank survival
test, resulting in a p-value of 0.0027 ().
(TIF)
S5 Fig. Effects of combination of CTLA4-Ig and IC87114 on cytokine production in
BDC2.5 CD4+ T cells. Cells isolated from the spleens and lymph nodes of BDC2.5 TCR trans-
genic NODmice were stimulated with the BDC2.5 mimotope (0.5 μg/mL) in the presence of
CTLA4-Ig (100 ng/mL) with or without increasing concentrations of IC87114 (0.6–10μM) for
48 hours. Cytokines from supernatants were assessed in duplicate using a bead cytokine array,
differences between groups were tested using the student t-test.
(TIF)
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